Drug Name: Sotyktu
Active Ingredient: deucravacitinib
Indications: To treat moderate-to-severe plaque psoriasis
Approval Date: 9/9/2022
Company: Bristol-Myers Squibb Company
Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214958s000lbl.pdf